Merck Trials, Tempus AI Deal And Leadership Shifts Shape Valuation Story [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck reported breakthrough pivotal Phase 3 results for Keytruda-based combinations in renal cell carcinoma and ovarian cancer. The company also announced positive clinical trial data for a new HIV treatment regimen. Merck entered a major precision medicine collaboration with Tempus AI focused on data driven drug discovery. The company implemented significant executive leadership changes affecting oncology, infectious diseases, and global operations. For investors watching NYSE:MRK, these updates come with the stock recently trading around $116.07 and a 1 year return of 28.1%. Over 5 years, the share price return of 91.2% shows how central Merck's oncology and infectious disease franchises have been to the story, with Keytruda a key piece of that. The fresh clinical and partnership news builds directly on this established foundation.
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial [Yahoo! Finance]Yahoo! Finance
- Akeso Deepens Cadonilimab Story With Survival Data And Global GBM Trial [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Evaxion announces business update and full year 2025 financial results [Yahoo! Finance]Yahoo! Finance
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website